Mitoglitazone
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Mitoglitazone
- Molecular weight
- 370.43
- Structure (SMILES)
- CCc1ccc(C(=O)COc2ccc(CC3SC(=O)NC3=O)cc2)nc1
- cay 10415
- CAY-10415
- j730 386f
- J730.386F
- mitoglitazone
- Mitoglitazone
- msd 9
- MSD-9
- msdc 0160
- msdc 0160 220 mg
- msdc 0160 90 mg
- MSDC-0160
- MSDC-0160 220 mg
- MSDC-0160 90 mg
- pnu 91325
- PNU-91325
- u 91325
- U-91325
- CAS registry numbers
- 146062-49-9
- ChEMBL ID
- CHEMBL146624
- InChIKey
- IRNJSRAGRIZIHD-UHFFFAOYSA-N
- PubChem compound IDs
- 10429242
- FDA ingredient codes (UNII)
- 29I7RP18RG
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- mitoglitazone
- Type
- Synthetic organic
- Drug name stem
- -glitazone
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- mitochondrial pyruvate carrier 1 like
- Gene symbol
- MPC1L
- Protein identifier
- P0DKB6
- Median affinity
- 5.57
- Affinity units
- pIC50
- Condition
- Alzheimer Disease
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004975
- Subject identifier
- D000544
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition identifier
- MONDO_0004975
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 2
- NCT00760578
- NCT01103414
- NCT01374438
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 1
- Polar surface area
- 85.36
- Calculated partition coefficient (ALogP)
- 2.8
- Calculated partition coefficient (XLogP)
- 3.5
- Prodrug
- No
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 7
- Heavy atoms
- 26
- Molecular formula
- C19H18N2O4S
- Monoisotopic mass
- 370.09872823
- Natural product
- Yes
- Recorded assays
- 14
- Active assays
- 2
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (5)
- 3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease
- A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator
- A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH
- A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
- Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients
In development for (2)
- Alzheimer disease Phase 2
- Type 2 diabetes mellitus Phase 2